[Back to Newsletter Page]
[Go to Main Page]

Ergoloid Mesylates Protect Brain Cells

E-Newsletter No. 20

Ergoloid mesylates, formerly known as Hydergine, are reported to increase mental abilities, prevent damage to brain cells from insufficient oxygen (hypoxia), and may even be able to reverse existing damage to brain cells.

Ergoloid mesylates are extracts from ergot, a fungus that grows on rye. Midwives in Europe traditionally used ergot with birthing mothers to lower their blood pressure. Researchers at the pharmaceutical giant Sandoz analyzed ergot, three were combined and tested for their anti-hypertensive properties. When studies with elderly people uncovered cognition-enhancing effects, Sandoz began spending a great deal of research money on Ergoloid mesylates. It is now one of the most popular treatments for all forms of senility in the U.S., and is used to treat a plethora of problems elsewhere in the world.

Ergoloid mesylates probably have several modes of action for their cognitive-enhancement properties. A wide variety of reported effects include the following:

1. Increasing blood supply and oxygen to the brain.

2. Enhancing brain cell metabolism.

3. Protecting the brain from free-radical damage during decreased or increased oxygen supply.

4. Speeding the elimination of age pigment (lipofuscin) in the brain.

5. Inhibiting free-radical activity.

6. Increasing intelligence, memory, learning, and recall.

7. Normalizing systolic blood pressure

8. Lowering abnormally high cholesterol levels in some cases.

9. Reducing symptoms of tiredness.

10. Reducing symptoms of dizziness and tinnitus (ringing in the ears).

One way that Ergoloid mesylates may enhance memory and learning is by mimicking the effect of a substance called nerve growth factor (NGF). NGF stimulates protein synthesis, resulting in the growth of dendrites (tiny extensions which branch out from brain cells making connections with other brain cells).

Dendrites are the communication connections between nerve and brain cells and are crucial to memory and learning.

Ergoloid mesylates was the first drug to show efficacy against Alzheimer’s disease (Branconnier, 1983). The efficacy of ergoloid mesylates in dementias is as well-proven as almost any drug used for treating psychiatric disorders (Hollister, 1988). At the time of a 1979 review, more than 20 double-blind placebo-controlled trials have been conducted to test ergoloid mesylates with senile dementias. All noted statistically significant improvements in behavioral and psychological parameters. Numerous favorable studies have been published since then. One recent study, however, reported no improvement in 39 Alzheimer’s patients who were treated with 1mg ergoloid mesylates three times per day for six months (Thompson, 1990). These negative results may be due to the disease having progressed beyond help, or perhaps because an inadequate dosage of ergoloid mesylates was used. In an earlier study of patients with multi-infarct dementias or mental disturbances following strokes, Yoshikawa and his colleagues (1983) demonstrated that a six-mg-per-day dose was far superior to the standard three-mg-per-day dose. The literature suggests that ergoloid mesylates treatment be started early in Alzheimer’s patients.

Precautions: If too large a dose is used when first taking ergoloid mesylates, it may cause slight nausea, gastric disturbance, or headache. Overall, ergoloid mesylates do not produce any serious side effects. It is nontoxic even at very large doses and are contraindicated only for individuals who have chronic or acute psychosis, or who are allergic to them. Over-dosage of ergoloid mesylates may, paradoxically, cause an amnesic effect.

Recommended Dose: 6mg daily

Take 2 capsules, three times a day or take 3 capsules, 2 times a day with or without meals.

To learn more about Mental Performance Improvement click here

[Back to Newsletter Page]
[Go to Main Page]